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Abbreviations: APC, antigen-presenting cells; CTL, cytotoxic T lymphocytes; DAMP, damage-associated molecular pattern;
DC, dendritic cells; IFN, interferon; IPS-1, IFNβ promoter stimulator-1; MDA5, melanoma differentiation associated gene 5;
Mf, macrophages; NK, natural killer; OVA, ovalbumin; PAMP, pathogen-associated molecular pattern; PRR, pattern-recognition receptors;
PV, poliovirus; RIG-I, retinoic acid inducible gene-1; SL8, an OVA tetramer; TICAM-1, Toll-IL-1 receptor homology domain-containing
molecule-1; TLR, Toll-like receptor; WT, wild-type
PolyI:C is a nucleotide pattern molecule that induces cross-presentation of foreign Ag in myeloid dendritic cells (DC) and
MHC Class I-dependent proliferation of cytotoxic T lymphocytes (CTL). DC (BM or spleen CD8a+) have sensors for dsRNA
including polyI:C to signal facilitating cross-presentation. Endosomal TLR3 and cytoplasmic RIG-I/MDA5 are reportedly
responsible for polyI:C sensing and presumed to deliver signal for cross-presentation via TICAM-1 (TRIF) and IPS-1 (MAVS,
Cardif, VISA) adaptors, respectively. In fact, when tumor-associated Ag (TAA) was simultaneously taken up with polyI:C in DC,
the DC cross-primed CTL specific to the TAA in a syngenic mouse model. Here we tested which of the TICAM-1 or IPS-1
pathway participate in cross-presentation of tumor-associated soluble Ag and retardation of tumor growth in the setting
with a syngeneic tumor implant system, EG7/C57BL6, and exogenously challenged soluble Ag (EG7 lysate) and polyI:C. When
EG7 lysate and polyI:C were subcutaneously injected in tumor-bearing mice, EG7 tumor growth retardation was observed in
wild-type and to a lesser extent IPS-12/2mice, but not TICAM-12/2mice. IRF-3/7 were essential but IPS-1 and type I IFN were
minimally involved in the polyI:C-mediated CTL proliferation. Although both TICAM-1 and IPS-1 contributed to CD86/CD40
upregulation in CD8a+ DC, H2Kb-SL8 tetramer and OT-1 proliferation assays indicated that OVA-recognizing CD8
T cells predominantly proliferated in vivo through TICAM-1 and CD8a+ DC is crucial in ex vivo analysis. Ultimately, tumor
regresses . 8 d post polyI:C administration. The results infer that soluble tumor Ag induces tumor growth retardation, i.e.,
therapeutic potential, if the TICAM-1 signal coincidentally occurs in CD8a+ DC around the tumor.
Introduction
Cytotoxic T lymphocytes (CTL) and natural killer (NK) cells are
two major effectors for antitumor cellular immunity. These
effectors are driven through activation of dendritic cells (DC) and/
or macrophages (Mf), which is mediated by pattern-recognition
receptors (PRRs) for the recognition of microbial patterns.1,2
Antigen (Ag) presentation and upregulation of NK cell-activating
ligands are major events induced in DC/Mf in response to PRRs,
which link to evoking CTL- and NK-antitumor immunity,
respectively. The immune-potentiating function of specific
components of the classical adjuvants are largely attributable to
the ligand activity of PRRs (CpG DNA/TLR9, polyI:C/TLR3,
monophosphoryl lipid (MPL) A/TLR4, Pam2/TLR2, etc.).3 That
is, the DC/Mf competent to drive effectors are generated through
PRR signal in inflammatory nest where affected cells and recruited
immune cells encounter exogenous or endogenous PRR ligands.
Since studying the functional properties of PRRs in tumor
immunity is on the way using a variety of possible ligands and cell
biological analyses, immune responses reflecting the total adjuvant
potential around Ag-presenting cells (APC) in local inflammatory
nests are not always elucidated even in mice.
RNA-sensing PRR pathways, including TLR3-TICAM-1,
TLR7-MyD88 and RIG-I/MDA5-IPS-1 participate in driving
Type I IFN induction and cellular immunity in DC subsets.1,4,5
Type I IFN and the IFNAR pathway in DC and other cells
reportedly evoke and amplify T cell immunity.5,6 TLR7 resides
exclusively in plasmacytoid DC7 whereas TLR3 mainly exists in
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myeloid DC/Mf and epithelial cells.8 They are localized on the
membrane of the endosome and deliver the signal via their
adaptors, MyD88 and TICAM-1.7,8 RIG-I and MDA5 are
ubiquitously distributed to a variety of mouse cells and signal the
presence of cytoplasmic viral products through IPS-1.9 Thus,
TLR3 and RIG-I/MDA5 are candidates associated with DC
maturation to drive effector cells.10 Indeed, viral dsRNA analog,
polyI:C, is a representative ligand for TLR3 and MDA5 and
induces polyI:C-mediated DC-NK reciprocal activation.11,12
These are also true in human DC.13
The point of this study is by which pathway antitumor CTL
are induced for tumor regression in a mouse tumor-implant
model. It has been postulated that DC present exogenous tumor
Ag to the MHC Class I-restricted Ag-presentation pathway and
proliferate CD8 T cells specific to the extrinsic Ag. When tumor
cells provide soluble and insoluble exogenous Ag, this Class I Ag
presentation occurs mostly TAP/proteasome-dependent, suggest-
ing the pathway partly sharing with that for endogenous Ag
presentation. This DC’s ability to deliver exogenous Ag to the
pathway for MHC Class I-restricted Ag presentation has been
described as cross-presentation.14 DC cross-presentation leads to
the cross-priming and proliferation of Ag-specific CD8 T cells in
vivo and in vitro.14-18 A variety of PAMP15,16 and intrinsic
DAMP17 as well as other factors including Type I IFN,5,18 CD4+
T cells19 and NKT cells20 augment cross-priming in tumor-
bearing mice. However, by what molecular mechanism polyI:C
enhances CTL induction in tumor-bearing mice remains largely
unsettled.
Here, we made an EG7 tumor-implant mouse system and
treated the mice with s.c.-injected ovalbumin (OVA)-containing
cell lysates (Ag) and polyI:C. Spleen CD8a+ DC turn CTL-
inducible when stimulated with Ag and polyI:C. In either case
of s.c., i.p., or i.v. injection of polyI:C, the TLR3/TICAM-1
pathway predominantly participates in CD8a+ DC cross-priming
and antitumor CTL induction. Earlier studies using non-tumor
models, suggested that both TLR3 and MDA5 appeared to
participate in polyI:C-dependent CTL induction.21 TLR3 is
predominantly involved in primary Ag response and Th1
skewing,22 while MDA5 participates in secondary Ag response.23
Importance of TLR3 in induction of cross-priming was first
suggested by Schulz et al., who used OVA/polyI:C-loaded or
virus-infected xenogenic (Vero) cells and mouse DC.16 Here we
demonstrate that the antitumor polyI:C activity is sustained by
the TICAM-1 pathway in any route of injection in tumor-
implant mice: antitumor CTL responses are mostly abrogated in
TICAM-12/2 but not IPS-12/2 mice.
Results
Properties of EG7 tumor with high MHC in tumor-loading
mice. The properties of the EG7 line we used are consistent with
those reported previously.24,25 It expressed high MHC Class I
(H2-Kb) and no Qa-1b or Rae-1 (Fig. S1). The expression
levels of these proteins were barely changed before and after
implantation of EG7 cells into mice. Cell viability was not
affected by in vitro stimulation with polyI:C only (Fig. S1B).
However, a batch-to-batch difference of cell viability may have
affected the rate of tumor growth in each mouse tumor-implant
experiment.
CD8+ T cells are responsible for tumor retardation by
polyI:C. EG7 cells (2  106) were inoculated into the back of
C57BL/6 (WT), and the indicated reagents were subcutaneously
(s.c.) injected around the EG7 tumor (Fig. 1A). Growth
retardation of tumor was observed by treatment with polyI:C or
polyI:C plus EG7 lysate (Fig. 1A). EG7 lysate only had no effect
on tumor regression. When CD8β+ T cells were depleted before
EG7 lysate/polyI:C treatment, polyI:C-mediated tumor growth
suppression was cancelled (Fig. 1A), suggesting the participation
of CD8 T cells in tumor growth suppression. The therapeutic
potential of polyI:C appeared to be more reproducible in the
presence of EG7 lysate than in the absence, judged from the
increases of activated CD8+ T cells (Fig. 1B) and cytotoxic activity
(Fig. 1C) of LN T cells isolated from the mice sacrificed after the
last therapy. Yet, the EG7 Ag could be more or less supplied from
the implant tumor. NK1.1+ cells did not participate in this EG7
tumor regression in this setting (data not shown).
Since EG7 lysate contains OVA, OVA-specific T cells in
draining LN and spleen of the WT mice were counted by
tetramer assay after the last therapy (Fig. S2A and B). The
numbers of tetramer-positive cells were prominently increased in
LN and spleen in mice with EG7 lysate and polyI:C. We
confirmed the importance of simultaneous administration of Ag
plus polyI:C for OVA-specific CTL induction as in Figure S2C,
where pure Ag (OVA) was used instead of EG7 lysate for
immunotherapy. The polyI:C adjuvant function appeared to be
more efficient in the mixture of pure Ag than in polyI:C alone.
Tumor regression (Fig. S2C) and OVA-specific CTL induction
(Fig. S2D) were clearly observed in this additional experiment. To
obtain reproducible data, we employed the EG7 lysate/polyI:C
combination therapy as follows.
IFN-inducing pathways are involved in PolyI:C-derived EG7
growth retardation. We next inoculated EG7 cells (2  106) into
the back of C57BL/6 (WT), TICAM-12/2, IPS-12/2, or
TICAM-1/IPS-1 double-deficient (DKO) mice (Fig. 2). We s.c.
administered EG7 lysate with or without polyI:C around the
tumor. The EG7 lysate was the soluble fraction of EG7 which
removed insoluble debris by centrifugation. The EG7 lysate
contained unprecipitated micro-debris and soluble Ag. No other
emulsified reagent was added for immunization. Thus, the
adjuvant function of polyI:C per se is reflected in the tumor
growth, although polyI:C had to be injected into mice twice a
week. Retardation of tumor growth was observed . 8 d after
immunization with EG7 lysate + polyI:C in WT mice, though no
growth retardation without polyI:C (Fig. 2A). The polyI:C-mediated
tumor growth suppression was largely abrogated in TICAM-12/2
(Fig. 2B) and to a lesser extent in IPS-12/2 mice (Fig. 2C), and
completely in TICAM-1/IPS-1 DKO mice (Fig. 2D). Hence,
TICAM-1 plays an important role in inducing polyI:C-mediated
tumor growth retardation in the s.c. setting we employed.
CD8 T cell activation induced by the TICAM-1 pathway.
CD8 T cell activation in the inguinal LN was tested with
polyI:C + EG7 lysate in EG7 tumor-bearing mice using CD69 as























an activating marker. Twenty-four hours after the last polyI:C +
EG7 sec.c. treatment, cells were harvested from the LN excised
(Fig. 3A). FACS profiles of total cells from each mouse group are
shown in Fig. S3. By combination therapy with EG7 lysate and
polyI:C, T cells were activated in WT and IPS-12/2 mice, but the
proportion of CD8 T cells was not affected by the therapy
(Fig. S4A). Under the same conditions, T cells were barely
activated in TICAM-12/2 mice in response to polyI:C (Fig. 3A).
The proportion of CD69+ cells are indicated in Figure 3B.
IL-2 (Fig. 3C) and IFNc (Fig. S4B) were highly induced in the
WT and IPS-12/2 LN cells, while they were
not induced in TICAM-12/2 or DKO cells.
IFNc levels were upregulated only in polyI:C-
treated tumor-bearing mice, although the
WT . IPS-12/2 profile for IFNc production
was reproducibly observed (Fig. S4B).
In vivo proliferation of CD8 T cells judged by
tetramer assay and IFNc induction. We next
tested whether i.p. injection of polyI:C plus OVA
induces CTL proliferation. PolyI:C and OVA
were i.p. injected into mice and the polyI:C-
dependent cross-priming of CD8 T cells were
examined using the OVA tetramer assay. OVA-
specific CD8 T cells were clonally proliferated in
WT and IPS-12/2 mice, but not in TICAM-1/
IPS-1 DKO and IRF-3/72/2 mice (Fig. 4A).
Proliferation of OVA-specific CD8 T cells
were severely suppressed in TICAM-12/2 mice
(Fig. 4A), suggesting that polyI:C-mediated cross-
priming of CD8 T cells largely depends on the
TICAM-1 pathway followed by IRF-3/7 activa-
tion in the i.p. route. The results were reproduced
in additional experiments using more mice
(Fig. 4B) and TLR32/2 mice (Fig. S5A and B).
The polyI:C cytokine response, where IFNa is
IPS-1-dependent while IL-12p40 is TICAM-1-
dependent, was also confirmed in serum level by
polyI:C i.p. injection (Fig. S5E). Specific induc-
tion of IFNc (Fig. 4C) was also observed in
parallel with the results of Figure 4A.
Whether or not i.v. injection of polyI:C plus
OVA induces Ag-specific CTL and cytotoxicity
was next checked. OVA-specific OT-1 proliferation
and cytotoxicity (Fig. 4D and E) were observed in
in vivo analyses of WT and IPS-12/2 CD8 T cells
but not of TICAM-12/2, TICAM-1/IPS-1 DKO,
and IRF-3/72/2 mice in the i.v. setting.
Since TICAM-1 is the adaptor for TLR3
as well as cytoplasmic helicases,24 we confirmed
the level of cross-priming being decreased in
TLR32/2 mice and an expected result was
obtained (Fig. S5A and B). Furthermore, in
IFNAR2/2 mice, OVA-specific CTL induction
was slightly reduced compared with that in WT
mice, but higher than in TICAM-12/2 mice
(Fig. S5C and D). Hence, in vivo cross-
presentation induced by polyI:C mostly depends on the TLR3-
TICAM-1 pathway followed by transcriptional regulation by
IRF-3/7 in any administration route, and is further promoted by
Type I IFN presumably produced by the stromal cells through the
IPS-1 pathway.26
IPS-1 induces DC maturation but not cross-priming in vivo.
Spleen DC maturation by i.v.-injected polyI:C was tested ex vivo
using CD8a+ DC and CD8a- DC isolated from WT or KO mice
with no tumor as indicated in Figure 5A. The maturation markers
CD86 and CD40 were upregulated on both CD8a+ and CD8a-
Figure 1. PolyI:C induces CTL-mediated tumor regression. (A) WT mice were challenged
with EG7 cells and were treated with PBS (●), EG7 lysates (▲), polyI:C (◆) and EG7 lysates +
polyI:C (■). The adjuvant therapy was started at the time indicated by the arrow and
the indicated reagents injected twice per week. One of the two PBS groups (○) and one of
the two EG7 lysates + polyI:C groups (◻) were treated with anti-CD8b ascites in order to
deplete CD8+ T cells once a week. Each group had 3–5 mice. (B) Draining inguinal LNs were
harvested 24 h after the last treatment and the proportion of CD69-expressing CD8+ cells
were counted. (C) LN cells were co-cultured with MMC-treated EG7 cells for 3 d and
subjected to 51Cr release assay to evaluate CTL activity. E/T = 50. All error bars used
in this figure show ± SEM. Data are representative of two independent experiments.
One-way analysis of variance (ANOVA) with Bonferroni’s test was performed to analyze
























DC from WT mice when they were stimulated with OVA and
polyI:C. Treatment of DC with OVA only did not induce
upregulation of CD86 and CD40. Although the expression levels
of CD86 and CD40 were a little less in CD8a+ and CD8a- DC
from TICAM-12/2 or IPS-12/2 mice than those from WT mice,
both CD86 and CD40 were sufficiently upregulated even in the
abrogation of either one pathway in polyI:C-injected mice. The
CD86 and CD40 shifts were completely abolished in DKO mice
(Fig. 5A). Thus, the TICAM-1 pathway participates in both
potent co-stimulation and cross-priming, while the IPS-1 pathway
mainly participates only in integral co-stimulation in myeloid DC.
We next assessed in vitro proliferation of OT-1 cells. CD8a+
and CD8a- DC were prepared from PBS, polyI:C, OVA and
OVA/polyI:C-treated mice, and mixed in vitro with CFSE-
labeled OT-1 cells. WT, TICAM-12/2 and IPS-12/2 mice were
used for this study. OT-1 proliferation was observed with CD8a+
DC but not CD8a- DC when OVA + polyI:C was injected
(Fig. 5B). Furthermore, the OT-1 proliferation barely occurred in
the mixture containing TICAM-12/2 CD8a+ DC. Thus, OT-1
proliferation is triggered by the TICAM-1 pathway in CD8a+
DC. Again, IPS-1 had almost no effect on OT-1 proliferation
with CD8a+ DC in this setting. In the mixture, IFNc was
produced in the supernatants of WT and IPS-12/2 CD8a+ DC
but not TICAM-12/2 DC by stimulation with OVA + polyI:C
(Fig. 5C). No IFNc was produced in the supernatants of CD8a-
DC even from WT mice, which results are in parallel with those
of OT-1 proliferation. In any case irrespective of tumor-bearing
or not, Ag, polyI:C and the TICAM-1 pathway are mandatory
for CD8a+ DC to cross-prime and proliferate OVA-specific CD8
T cells.
We checked the TICAM-1- or IPS-1-specific gene expressions
related to Type I IFN and MHC Class I presentation using
genechip and qPCR (Fig. S6). PolyI:C-mediated upregulation of
Tap1, Tap2 and Tapbp messages diminished in TICAM-12/2
BMDC (Fig. S6A). The levels of these genes were hardly
affected in IPS-12/2 BMDC (data not shown). PolyI:C-mediated
upregulation was observed with MDA5 (Ifih1) in CD8a- and
CD8a+ DCs (Fig. S6B). Surprisingly, other factors including
TLR3, TICAM-1 and MAVS messages were all downregulated in
response to polyI:C in CD8a+ DC (Fig. S6B), for the reason as
yet unknown.
Effect of TLR3-mediated IFN-inducing pathway on anti-
tumor CTL induction. PolyI:C is a dsRNA analog capable of
incorporating into the endosome and cytoplasm by exogenous
administration in vitro.27,28 However, no evidence has been
proposed that polyI:C is internalized into the endosome of
Figure 2. PolyI:C-induced tumor retardation is dependent on the TICAM-1 pathway. Antitumor effect of polyI:C on various KO mice were evaluated
by using in vivo mouse tumor implant model. EG7 cells were inoculated to WT (A), TICAM-12/2 (B), IPS-12/2 (C) and DKO mice (D) on day 0. PBS (●),
EG7 lysates (▲) or EG7 lysates + polyI:C (■) were s.c. administered around the tumor. The adjuvant therapies were started at the time indicated
by the arrows and injected twice per week. Each group have 3–4 mice and error bar shows ± SEM. Data are representative of two independent
experiments. **, p , 0.01























Figure 3. CD8 T cells in the draining LNs are activated through the TICAM-1 pathway by polyI:C. Draining inguinal LNs were harvested from tumor-
bearing mice 24 h after the last treatment. LN cells were stained with CD3ε, CD8a and CD69, and the cells gated on CD3ε+CD8a+ are shown (A). Spleen
cells in each group of mice were stained separately, the CD8 levels in gated cells being variably distributed in FACS analyses. The average frequency
of activated CD8 T cells defined by CD69 expression is shown (B). Alternatively, LN cells from the indicated mice were cultured for further 3 d in vitro and
























Figure 4. TICAM-1 and IRF-3/7 are essential for polyI:C-induced antigen-specific CTL expansion. WT, TICAM-12/2, IPS-12/2, TICAM-1/IPS-1 DKO and
IRF-3/72/2 mice were i.p. administered with the combination of OVA and polyI:C. After 7days, splenocytes were harvested and stained with CD8a and
OVA tetramer (A). The average percentages of OVA-specific CTL are shown (B). Alternatively, splenocytes were cultured in vitro in the presence of SL8
for 8 h and IFNc production was measured by intracellular cytokine staining (C). To assess the killing activity, in vivo CTL assay was performed.
The combinations of OVA and polyI:C were administered i.v. to each group of mice and 5 d later, cytotoxicity was measured (D). The data shown are
collaborate or representative of at least three independent experiments. One-way analysis of variance (ANOVA) with Bonferroni’s test was performed to
analyze statistical significance. *, p , 0.05; **, p , 0.01; ***, p , 0.001.























CD8a+ DC where TLR3 is expressed in vivo.
Peritoneal (PEC) Mf and bone marrow-derived
DC22 usually phagocytoze polyI:C and deliver them
into the endosome. In mouse CD8a+ DC direct
internalization of polyI:C has remain unproven.
Using labeled polyI:C and anti-mouse TLR3 mAb,
11F8,22 we checked whether the exogenously-added
polyI:C encountered with TLR3 in CD8a+ DC in
vitro. TLR3 (green) was merged with TexasRed-
polyI:C 30–120 min after polyI:C stimulation in
the culture (Fig. 6A). The quantities of CD8a+ and
CD8a- DC where FITC-polyI:C was incorporated
were determined by FACS analysis (Fig. 6B). Thus,
the process by which polyI:C injected reaches the
endosomal TLR3 is delineated in the CD8a+ DC.
Discussion
PolyI:C is an analog of virus dsRNA, and acts as a
ligand for TLR3 and RIG-I/MDA5. PolyI:C has
been utilized as an adjuvant for enhancement of
antitumor immunity for a long time.29 However,
the mechanistic background of the therapeutic
potentials of polyI:C against cancer has been poorly
illustrated. It induces antitumor NK activation
through DC-NK cell-to-cell interaction when
CD8a+ DC TLR3 is stimulated in the spleen.11
Besides myeloid cells, however, some tumor cell
lines express TLR3 and dsRNA targeting tumor
cells may affect the growth rate of tumors,30 where
the receptor-interacting protein (RIP) pathway is
involved downstream of TICAM-1.31 Here we
showed evidence that polyI:C injection facilitates
maturation of TLR3-positive CD8a+ DC (i.e.,
APC) to trigger CTL induction against exogenous
soluble Ags including EG7 lysate or OVA. The
TICAM-1 adaptor for TLR3 and IRF-3/7 are
involved in the cross-presentation signal in CD8a+
DC, but the molecule/mechanism downstream of
TICAM-1 that governs cross-presentation remains
elusive. Since most of the tumor-associated Ags
(TAA) are predicted to be liberated from tumor cells
Figure 5. TICAM-1 in CD8a+ DC is more important than
IPS-1 in polyI:C-induced cross-priming. OVA and polyI:C
were administered i.v. and 4 h later, CD8a+ and CD8a- DC
were isolated from the spleen. CD86 and CD40 expres-
sions were determined by FACS (A). Filled gray and black
line show isotype control and target expression,
respectively. Alternatively, CD8a+ and CD8a- DC were
co-cultured with CFSE-labeled RAG22/2/OT-1 T cells for
3 d. The cross-priming activity of each DC subset was
determined with sequential dilution of CFSE (B) and IFNc
production (C). IFNc was measured by CBA assay.
The data shown are representative of two independent
























as soluble Ags, the TICAM-1 pathway in CD8a+ DC would be
crucial for driving of tumor-specific CTL around the tumor
microenvironment. In any route of polyI:C injection, this is true
as shown first in this study. Although TICAM-1 is an adaptor
of other cytoplasmic sensors, DDX1, DDX21 and DHX36,32
the antitumor CTL responses are merely relied on TLR3 of
CD8a+DC in this system. Taken together with previous
reports,11,12 TICAM-1 signaling triggers not only NK activation
but also CTL induction.
TLR3 and MDA5 are main sensors for dsRNA and
differentially distributed in myeloid cells.33,34 TLR3 is
limitedly expressed in myeloid, epithelial and neuronal
cells,33 whereas MDA5 is ubiquitously expressed including
non-myeloid stromal cells.33 Several reports suggested that
i.v. injection of polyI:C predominantly stimulate the
stromal cells which express IFNAR,26 thereby robust
type I IFN are liberated from these cells to be a systemic
response including cytokinemia and endotoxin-like
shock.35,36 Both TLR3 and MDA5 link to the IRF-3/7-
activating kinases leading to the production of IFNa/β.37,38
Once IFNa/β are released, IFNAR senses it to amplify the
Type I IFN production,39 and reportedly this amplification
pathway involves cross-priming of CD8 T cells in viral
infection.18 Tumor progression or metastasis can be
suppressed through the IFNAR pathway.40 These scenarios
may be right depending on the conditions employed. Our
message is related to what signal pathway is fundamentally
required for induction of antitumor CTL in DC. The CTL
response is almost completely abrogated in TICAM-12/2
and IRF-3/72/2 mice, but largely remains in IPS-12/2 and
IFNAR2/2 mice when Ag and polyI:C are extrinsically
administered. The results are reproducible in some other
tumor-implant models (data not shown), and even in
IFNAR2/2 mice, TICAM-1-specific genes are upregulated
to confer tumor cytotoxicity (Fig. S6, Azuma et al.,
unpublished data). In addition, the upregulation of these
genes is independent of IPS-1 knockout in DC. Our results
infer that the primary sensing of dsRNA in CD8a+ DC is
competent to induce cross-presentation, which minimally
involves the IPS-1 or IFNAR amplification pathway, at
least at a low dose of polyI:C. Yet, subsequent induction of
Type I IFN via the IFNAR may further amplify the cross-
priming.18,41 Further studies are needed as to which of the
TICAM-1-inducible genes link to the cross-presentation in
CD8a+ DC.
The main focus of this study was to identify the pathway
for transversion of immature DC to the CTL-driving
phenotype by co-administration of polyI:C with soluble
Ag. The IPS-1 pathway, although barely participates in
antitumor CTL driving, can upregulate CD40/CD86 co-
stimulators on the membranes of splenic CD8a+ and
CD8a- DC in response to polyI:C, suggesting that MDA5
does function in the cytoplasm of splenic CD8a+ and
CD8a- DC to sense polyI:C. However, effective CTL
induction happens only in CD8a+ DC when stimulated
with polyI:C. CD8a+ DC express TLR3 but CD8a- DC
do not, and CD8a+ DC with no TLR3 fail to induce CTL,
suggesting that integral co-stimulation by MDA5/IPS-1 is
insufficient for DC to induce cross-priming of CD8 T cells:
antitumor CTL are not induced until the TICAM-1 signal is
provided in DC. At least, sole effect of the IPS-1 pathway and
upregulation of co-stimulators on CD8a+ DC is limited for cross-
priming and induction of antitumor CTL, which result partly
reflects those in a previous report where IPS-1 and TICAM-1
harbor a similar potential for CD8 T cell proliferation when
Figure 6. PolyI:C encounters TLR3 in CD8a+ DC. CD8a+ and CD8a- DC were
isolated by FACSAriaII and stimulated with 20 mg/ml TexasRed-polyI:C for 2 h.
Then cells were stained with Alexa647-antiTLR3 and subjected to confocal
microscopic analysis (A). Alternatively, splenic DC isolated by MACS were
incubated with FITC-polyI:C for the time shown in figure and analyzed
the degrees of polyI:C uptake by FACS (B). Data shown are the representative
of three independent experiments.























polyI:C (Alum-containing) is employed as an adjuvant for CD8a+
DC to test proliferation of anti-OVA CTL.21
A question is why TICAM-1 is dominant to IPS-1 for response
to exogenously-added polyI:C in CD8a+ DC. The answer is
rooted in the difference of functional behavior between BMDC
and CD8a+ DC. TLR3 levels are variable depending upon subsets
of DC,22 which affects DC subset-specific induction of cellular
immune response. The high TLR3 expression (partly surface-
expressed) is situated in CD8a+ DC before polyI:C stimulation,
which is distinct from the properties of F4/80+ Mf and
presumably BMDC of low TLR3 expression. The polyI:C-uptake
machinery15 appears to efficiently work in concert with the
TLR3/TICAM-1 pathway in CD8a+ DC and this tendency
is diminished when CD8a+ DC are pretreated with Alum +
polyI:C.21 Furthermore, there are functional discrepancies
between CD8a+ splenic DC and GM-CSF-induced BMDC,
which appears to reflect the difference of their TLR3 levels.22
These results on CD8a+ DC encourage us to develop dsRNA
adjuvant immunotherapy supporting TAA soluble vaccines for
cancer applicable to humans, which possess the counterpart of
CD8a+ DC.
There are two modes of dsRNA-mediated DC maturation,
intrinsic and extrinsic modes that are governed by the IPS-1 and
TICAM-1 pathways, respectively.9,34 It is important to elucidate
the in vivo qualitative difference in the two pathways in tumor-
loading mice. TLR3+ DC/Mf are responsible for CTL driving via
an extrinsic route in viral infection.34 Previous data suggested that
dsRNA in infectious cell debris, rather than viral dsRNA
produced in the cytoplasm of Ag-presenting cells or autophago-
some formation, contribute to fine tuning of DC maturation
through extrinsic dsRNA recognition.16 It is reported that
dsRNA-containing debris are generated secondary to infection-
mediated cell death,41 and DC phagocytose by-stander dead cells.
Likewise, soluble tumor Ags released from tumor cells usually are
extrinsically taken up by APC in patients with cancer.42 If CTL
are successfully induced in therapeutic biotherapy targeted against
cancer cells, this extrinsic TICAM-1 pathway must be involved in
the therapeutic process.
Cross-presentation occurs in a TAP-dependent43 and -inde-
pendent fashions.44,45 The peptides are transported by TAP into
the endoplasmic reticulum (ER) and loaded onto MHC Class I
for presentation at the cell surface. ER and phagosome might fuse
each other for accelerating cross-presentation.46 Another possibi-
lity is that cross-presentation occurs in early endosomes where
TLR3 resides. This early endosome cross-presentation does not
always depend on TAP42-44 but requires TLR stimulation.34
TLR4/MyD88 pathway is involved in the TAP-dependent early
endosome model,43 where recruitment of TAP to the early
endosomes is an essential step for the cross-presentation of soluble
Ag. These models together with our genechip analysis of polyI:C-
stimulated BMDC suggested that some ER-associated proteins are
upregulated in BMDC by polyI:C-TICAM-1 pathway. The
results infer that the TLR3/TICAM-1 rather than the TLR4/
MyD88 pathway more crucially participates in cross-presentation
in response to dsRNA or viral stimuli and facilitates raising CTL
antitumor immunity in APC.
Although multiple RNA sensors couple with TICAM-1 and
signal to activate the Type I IFN-inducing pathway,25 at least
TLR3 in the CD8a+ DC are critical in CTL driving. CD8a+ DC
are a high TLR3 expresser, while BMDC express TLR3 with only
low levels.22 CD8a- DC do not express it.22 The Ag presentation
and TLR3 levels in CD8a+ DC appear reciprocally correlated
with the phagocytosing ability of DC. Although the TLR3
mRNA level is downregulated secondary to polyI:C response after
maturation, this may not be related to the CD8a+ DC functions.
Yet, polyI:C might interact with other cytoplasmic sensors for DC
maturation,32,47
The route of administration and delivery methods may be
important for culminate the polyI:C adjuvant function. The toxic
problem has not overcome in the adjuvant therapy using polyI:
C35,36 and this is a critical matter for clinical introduction of
dsRNA reagents to immunotherapy. The most problematic is the
life-threatening shock induced by polyI:C. Recent advance of
polyI:C study suggests that PEI-jet helps efficient uptake of polyI:
C into peritoneal macrophages.48 LC (poly-L-lysine and methyl-
cellulose) has been used as a preservative to reduce the toxic effect
of polyI:C.49 Nanotechnological delivery of polyI:C results in
efficient tumor regression.50 There are many subsets of DC that
can be defined by surface markers, and selecting an appropriate
administration route can target a specific DC subset. The route
for s.c. administration usually mature dermal/epidermal DC or
Langerhans cells.51,52 Some DC subsets with unique properties
specialized to CTL induction would work in association with the
route of polyI:C administration. Attempting to develop more
harmless and efficient dsRNA derivatives will benefit for
establishing human adjuvant immunotherapy for cancer.
Materials and Methods
Mice. TICAM-12/2 and IPS-12/2 mice were made in our
laboratory and backcrossed more than eight times to adapt
C57BL/6 background.12 IRF-3/72/2 and IFNAR2/2 mice were
kindly provided by T. Taniguchi (University of Tokyo, Tokyo,
Japan). TLR32/2 mice were kindly provided by S. Akira (Osaka
University, Osaka, Japan). Rag22/2 and OT-1 mice were kindly
provided from Drs N. Ishii (Tohoku University, Sendai, Japan).
Rag22/2/OT-1 mice were bred in our laboratory. All mice
were maintained under specific pathogen-free conditions in the
animal facility of the Hokkaido University Graduate School
of Medicine. Animal experiments were performed according
to the guidelines set by the animal safety center, Hokkaido
University, Japan.
Cells. EG7 and C1498 cells were purchased from ATCC and
cultured in RPMI1640/10% FCS/55 mM 2-ME/1 mM sodium
pyruvate and RPMI1640/10% FCS/25 ng/ml 2-ME, respectively.
Mouse splenocytes, OT-1 T cell, CD8a+ DC and CD8a- DC
were harvested from the spleen and cultured in RPMI1640/10%
FCS/55 mM 2-ME/10 mM HEPES.41 B16D8 cells were cultured
in RPMI/10% FCS as described previously.12
Reagents and antibodies. Ovalbumin (OVA) and polyI:C
(polyI:C) were purchased from SIGMA and Amersham
























and OVA (H2Kb-SL8) Tetramer were from MBL. Following Abs
were purchased: anti-CD3ε (145-2C11), anti-CD8β (53-6.7),
anti-CD11c (N418), anti-CD16/32 (93), anti-CD69 (H1.2F3)
and anti-IFNc(XMG1.2) Abs from BioLegend, anti-B220 (RA3-
6B2), anti-CD4 (L3T4), anti-CD40 (1C10), anti-CD86 (GL1),
and anti-MHC I-SL8 (25-D1.16) Abs from eBiosciences, anti-
TCR-Vβ5.1/5.2 Ab and ViaProbe from BD Biosciences. The Rat
anti-mouse TLR3 mAb (11F8) was kindly provided by David M.
Segal (National Institute of Health, Bethesda, MD). To rule out
LPS contamination, we treated OVA or other reagents with
200 mg/ml of Polymixin B for 30 min at 37°C before use. Texas
Red- or FITC-labeled poly(I:C) was prepared using the 5'
EndTagTM Nucleic Acid Labeling System (Vector Laboratories)
according to the manufacturers instructions.
Tumor challenge and poly I:C therapy. Mice were shaved at
the back and s.c. injected with 200 ml of 2  106 syngenic EG7
cells in PBS. Tumor volumes were measured at regular intervals
by using a caliper. Tumor volume was calculated by using the
formula: Tumor volume (cm3) = (long diameter)  (short
diameter)2  0.4. A volume of 50 ml of a mixture consisting of the
lysate of 2  105 EG7 cells with or without 50 mg of poly I:C
(polyI:C) was s.c. injected around the tumor. We added no other
emulsified reagent for immunization since we want to role out the
conditional effect of the Ag/polyI:C. The treatments were started
when the average of tumor volumes reached at 0.4–0.8 cm3 and
performed twice per week. EG7 lysate were prepared by three
times freeze/thaw cycles (-140°C/37°C) in PBS, with removal of
cell debris by centrifugation at 6,000 g for 10 min.53 To deplete
CD8 T cells, mice were i.p. injected with hybridoma ascites of
anti-CD8β mAb. The dose of antibody and the treatment
regimens were determined in preliminary studies by using the
same lots of antibody used for the experiments. Depletion of the
desired cell populations by this treatment was confirmed by FACS
for the entire duration of the study.
Evaluation of T cell activity in tumor-bearing mice. Draining
inguinal LN cells were harvested from tumor-bearing mice after
24 h from the last polyI:C treatment. The activity of T cells was
evaluated by CD69 expression and IL-2/IFNc production. These
cells were stained with FITC-CD8a, PE-CD69, PerCP/Cy5.5-
7AAD and APC-CD3ε. To check cytokine production, LN cells
were cultured for 3 d in vitro in the presence or absence of EG7
lysates and IL-2 and IFNc productions were determined by
Cytokine Beads Array (CBA) assay (BD). To assess the cytotoxic
activity of CTL, standard 51Cr release assay was performed.
For CTL expansion, 2.5  106 LN cells were co-cultured with
1.25  105 mitomycin C-treated EG7 cells in the presence of
10 U/ml IL-2 for 5 d. Then, LN cells were incubated with
51Cr-labeled EG7 or C1498 cells for 4 h and determined cytotoxic
activity. The cell-specific cytotoxicity was calculated with
subtracting the cytotoxity for C1498 from for EG7 cells.
Antigen-specific T cell expansion in vivo. Mice were i.p.
immunized with 1 mg of OVA and 150 mg of poly I:C. After 7 d,
spleens were homogenized and stained with FITC-CD8a and
PE-OVA Tetramer for detecting OVA-specific CD8 T cell
populations. For intracellular cytokine detection, splenocytes
were cultured with or without 100 nM OVA peptide (SIINFEKL;
SL8) for 8 h and 10 mg/ml of Brefeldin A (Sigma-Aldrich)
was added to the culture in the last 4 h. Then cells were
stained with PE-anti-CD8a and fixed/permeabilized with
Cytofix/Cytoperm (BD Biosciences) according to manufacturer’s
instruction. Then, fixed/permeabilized cells were further
stained with APC-anti-IFNc. Stained cells were analyzed
with FACSCalibur (BD Biosciences) and FlowJo software (Tree
Star).
In vivo CTL assay. The in vivo CTL assay was performed
as described.54 In brief, WT, TICAM-12/2, MAVS2/2 and
IRF-3/72/2 mice were i.v. administered with PBS, 10 mg of OVA
or OVA with 50 mg of polyI:C. After 5 d, 2  107 target cells (see
below) were i.v. injected to other irrelevant mice and 8 h later, the
OVA-specific cytotoxicity was measured by FACSCalibur. Target
cells were 1:1 mixture of 2 mM SL8-pulsed, 5 mM CFSE-labeled
splenocytes and SL8-unpulesed, 0.5 mM CFSE-labeled spleno-
cytes. OVA-specific cytotoxicity was calculated with a formula:
{1-(Primed [CFSEhigh(%)/CFSElow(%)]/Unprimed [CFSEhigh(%)/
CFSElow(%)]}  100.
DC preparation. DCs were prepared from spleens of mice, as
described previously.55 In brief, collagenase-digested spleen cells
were treated with ACK buffer and then washed with PBS twice.
Then splenocytes were positively isolated with anti-CD11c
MicroBeads. CD11c+ cells were acquired routinely about $
80% purity. Further, to highly purify CD8a+ and CD8a- DCs,
spleen DC were stained with FITC-CD8a, PE-B220, PE/Cy7-
CD11c and PerCP5.5-7AAD. CD8a+ or CD8a- CD11c+B220-
DCs were purified on FACSAriaII (BD). The purity of the cells
was $ 98%.
OT-1 proliferation assay. Ten micrograms of OVA with or
without 50 mg of polyI:C were i.v. injected to WT, TICAM-12/2,
IPS-12/2 and DKO mice. After 4 h, CD8a+ or CD8a- DC were
purified from the spleen. 2.5  104 CD8a+ or CD8a- DC were
co-cultured with 5  104 1 mM CFSE-labeled Rag22/2/OT-1
T cells for 3 d in 96-well round bottom plate. These cells were
stained with PE-anti-TCR-Vβ5.1,5.2 and APC-anti-CD3ε and
T cell proliferation was analyzed by CFSE dilution using
FACSCalibur. Additionally, IFNc in the culture supernatant
was measured by CBA assay.
Statistical analysis. P-values were calculated with one-way
analysis of variance (ANOVA) with Bonferroni’s test. Error bars
represent the SD or SEM between samples.
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